Erdosteine

Generic Name
Erdosteine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C8H11NO4S2
CAS Number
84611-23-4
Unique Ingredient Identifier
76J0853EKA
Background

Erdosteine is a drug that causes a breakdown of mucus, also known as a mucolytic agent. It is a thiol derivative produced for the clinical management of chronic obstructive bronchitis, in addition to infective exacerbations of chronic bronchitis. This drug contains sulfhydryl groups which are released after erdosteine undergoes hepatic first pass metabolism. Three active metabolites result and possess mucolytic activity in addition to free radical scavenging activity. Erdosteine acts to control mucus production and control its viscosity while increasing mucociliary transport. It also combats the effects of free radicals resulting from cigarette smoke. Erdosteine has been shown to be safe and well tolerated in clinical trials. Erdosteine 300mg twice daily reduced cough (both frequency and severity) and sputum viscosity more quickly and more effectively than placebo and reduced the adhesivity of sputum more effectively than ambroxol 30mg twice daily. Co-administration of erdosteine and amoxicillin in patients with acute infective exacerbation of chronic bronchitis resulted in higher concentrations of the antibiotic in the sputum, leading to earlier and more pronounced amelioration of clinical symptoms compared with placebo. Erdosteine is associated with a low incidence of adverse events, most of which are gastrointestinal and generally mild.

Indication

Fro the treatment of chronic bronchitis in adults.

Associated Conditions
Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy

Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Erdosteine for Treatment of Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)

First Posted Date
2010-08-06
Last Posted Date
2019-06-19
Lead Sponsor
Hull University Teaching Hospitals NHS Trust
Registration Number
NCT01176318
Locations
🇬🇧

Castle Hill Hospital, Cottingham, East Yorkshire, United Kingdom

The Efficacy and Safety of Erdosteine in Chronic Obstructive Pulmonary Disease (COPD)

First Posted Date
2009-12-15
Last Posted Date
2014-06-13
Lead Sponsor
Edmond Pharma
Target Recruit Count
492
Registration Number
NCT01032304
Locations
🇨🇿

Poliklinica Moravsky Krumlov, Moravsky Krumlov, Czech Republic

🇧🇬

Clinic of Pulmonary Disease-Military Medical Academy, Sofia, Bulgaria

🇧🇪

Campus Gasthuisberg Dep.t Longfunctiemetingen, Leuven, Belgium

and more 41 locations

Phase 2 Study - Erdosteine in Patients With CB/COPD

First Posted Date
2006-06-20
Last Posted Date
2007-12-06
Lead Sponsor
Adams Respiratory Therapeutics
Target Recruit Count
400
Registration Number
NCT00338507
Locations
🇺🇸

Omnicare Clinical Research, King of Prussia, Pennsylvania, United States

© Copyright 2024. All Rights Reserved by MedPath